Developer docs
API playgroundTry for free, no card

Search company profiles

Septerna

Full company profile

uuid00004tq

Namestring
Septerna
Legal namestring
Septerna, Inc.
Websiteurl
septerna.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Septerna is a clinical-stage biotechnology company developing oral small molecule drug candidates that target G protein-coupled receptors (GPCRs), the largest family of cell membrane receptors and the target class for roughly one-third of all FDA-approved drugs. The company pursues a wholly-owned pipeline spanning endocrinology (SEP-479, an oral PTH1R agonist for hypoparathyroidism, and an oral TSHR negative allosteric modulator for Graves' disease and thyroid eye disease), immunology and inflammation (SEP-631, an oral MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell-driven diseases), and a partnered metabolic disease franchise under a global collaboration with Novo Nordisk covering five GPCR targets including GLP-1, GIP and glucagon receptors for obesity and cardiometabolic indications.

At the core of the company is the proprietary Native Complex Platform®, an industrial-scale drug discovery system that isolates, purifies and reconstitutes GPCRs outside of cells into complexes with ligands, transducer proteins and lipid bilayers, replicating native receptor structure and dynamics in a purified biochemical format. The platform integrates high-resolution cryo-EM structure determination with ultra-large-scale computational screening of billions of candidate molecules, biochemical screening via DNA-encoded libraries, and iterative structure-based drug design, and is supported by the scientific leadership of co-founder Robert Lefkowitz (Nobel laureate in GPCR research) alongside co-founders Arthur Christopoulos, Patrick Sexton and CEO Jeffrey Finer.

Septerna is pre-commercial and generates revenue primarily from collaboration agreements and asset sales rather than product sales. The dominant revenue stream is the May 2025 Novo Nordisk global collaboration and license agreement (~$2.2B total potential value: $195M upfront, up to ~$500M per program in milestones, plus tiered royalties on global net sales), with prior non-dilutive capital from the September 2023 sale of an undisclosed discovery-stage GPCR program to Vertex Pharmaceuticals for $47.5M upfront. Future product sales will rely on a hybrid GTM model combining independent commercialization of wholly-owned assets (SEP-479, SEP-631, TSHR program) with partner-led commercialization for the metabolic franchise, where Novo Nordisk funds all R&D expenses and brings established global commercial infrastructure. The company is publicly traded on NASDAQ under ticker SEPN following a 2024 IPO that raised $331M, and operates from South San Francisco with 51–100 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
GPCR drug discovery, oral small molecules, clinical-stage biotechnology, structure-based drug design, cryo-EM drug discovery
Industry1 code
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage biotechnology — GPCR-targeted therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Collaboration Revenue
TypeLicensing Royalties
Description

Revenue generated from strategic partnerships with pharmaceutical companies including upfront payments, research and development funding, milestone payments, and tiered royalties on net sales of commercialized products. The company receives collaboration revenue from its Novo Nordisk partnership ($195M upfront plus potential milestones up to ~$500M per program plus royalties).

globenewswire.com
2Outbound Licensing and Asset Sales
TypeLicensing Royalties
Description

Revenue from licensing or selling GPCR programs to pharmaceutical partners, including upfront payments and potential milestone payments. Example: Vertex Pharmaceuticals acquired an undisclosed discovery-stage GPCR program for $47.5M upfront plus potential preclinical milestones.

septerna.com
3Future Product Sales
TypeOne Time License
Description

Pre-commercial stage. The company is developing a pipeline of oral small molecule GPCR-targeted drug candidates that will be commercialized independently or through partnerships once approved. Peak sales projections for lead programs include SEP-631 ($3.2B for CSU) and SEP-479 ($2.5B for hypoparathyroidism).

seekingalpha.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Septerna is a clinical-stage biotechnology company that discovers and develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform®. The company is advancing a pipeline of wholly-owned programs across endocrinology (SEP-479 for hypoparathyroidism, TSHR Program for Graves' disease/thyroid eye disease), immunology and inflammation (SEP-631 for chronic spontaneous urticaria and mast cell-driven diseases), and metabolic diseases via a global partnership with Novo Nordisk covering five GPCR targets including GLP-1, GIP, and glucagon receptors for obesity and cardiometabolic indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • SEP-631 demonstrated complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once-daily in Phase 1 trial
+3 more records
Product overview1 text field

Septerna is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform®. The company's wholly-owned pipeline focuses on three therapeutic areas: endocrinology (SEP-479 for hypoparathyroidism, TSHR Program for Graves' disease and thyroid eye disease), immunology and inflammation (SEP-631 for chronic spontaneous urticaria and other mast cell-driven diseases), and metabolic diseases (via partnership with Novo Nordisk targeting GLP-1, GIP, and glucagon receptors for obesity and cardiometabolic diseases). Septerna develops oral small molecule drug candidates designed to have disease-modifying potential with distinct mechanisms of action including agonists and negative allosteric modulators targeting G protein-coupled receptors.

Product and service5 records
1Native Complex Platform®
CategoryDrug discovery platform
Description

A proprietary industrial-scale drug discovery platform that enables the isolation, purification, and reconstitution of GPCRs outside of cells into complexes with ligands, transducer proteins, and lipid bilayers. The platform utilizes cryogenic electron microscopy for high-resolution 3D GPCR structure determination and supports screening of billions of candidate molecules through ultra-large-scale computational screens and DNA-encoded library biochemical screens, enabling structure-based drug design for previously difficult-to-drug GPCR targets.

2SEP-479 (PTH1R agonist)
CategoryClinical-stage drug candidate (endocrinology)
Description

An oral small molecule agonist targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. Designed to offer a convenient, functional replacement for PTH by activating PTH1R in bones and kidneys to restore normal calcium control, providing an oral alternative to injectable peptide-based therapies for the approximately 70,000 U.S. and 140,000 European patients affected by the disease.

3SEP-631 (MRGPRX2 NAM)
CategoryClinical-stage drug candidate (immunology/inflammation)
Description

An oral small molecule negative allosteric modulator (NAM) that inhibits the Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases including atopic dermatitis, interstitial cystitis, migraine, and asthma. Targeted at approximately 1.5 million U.S. patients with CSU.

4TSHR Program
CategoryDiscovery-stage drug candidate (endocrinology)
Description

An oral small molecule negative allosteric modulator (NAM) targeting the thyroid-stimulating hormone receptor (TSHR) being developed for both Graves' disease and thyroid eye disease, offering a novel disease-modifying treatment approach for the over 2 million U.S. patients with Graves' disease, of whom approximately 50% develop thyroid eye disease.

5Metabolic Programs (Novo Nordisk Collaboration)
CategoryPartnered drug programs (metabolic diseases)
Description

Global collaboration with Novo Nordisk to discover, develop and commercialize oral small molecule medicines for obesity and other cardiometabolic diseases, spanning five GPCR targets including GLP-1, GIP, and glucagon receptors. Septerna received $195 million upfront and is eligible for up to approximately $500 million in research, development and commercial milestone payments per program, plus tiered royalties on global net sales. Novo Nordisk is responsible for all R&D expenses.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Global collaboration and license agreement announced May 2025 to discover, develop and commercialize oral small molecule medicines for obesity and other cardiometabolic diseases. Programs span five GPCR targets including GLP-1, GIP, and glucagon receptors. Septerna received $195M upfront payment and is eligible for up to approximately $500M in research, development and commercial milestone payments for each program, plus tiered royalties on global net sales. Novo Nordisk responsible for all R&D expenses.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Asset purchase agreement signed September 2023 under which Vertex acquired an undisclosed discovery-stage GPCR program. Septerna received $47.5M upfront payment and is eligible for additional payments related to use of the company's GPCR Native Complex Platform® and a preclinical milestone. Vertex responsible for continuing R&D of the novel GPCR program.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing oral small molecule therapeutics targeting GPCRs, with a leading GLP-1 program for obesity and diabetes. Directly comparable to Septerna given the shared focus on oral small molecules against validated GPCR targets and similar cardiometabolic positioning.

TypeDirect peer
Description

Clinical-stage biotech developing oral small molecule drugs targeting GPCRs in endocrinology and rare diseases, including acromegaly and hyperinsulinism programs. Highly comparable to Septerna's SEP-479 hypoparathyroidism positioning and oral small molecule GPCR strategy.

3Sosei Heptares
TypeDirect peer
Description

Japan-headquartered GPCR-focused drug discovery company with a proprietary StaR® structural platform for stabilizing GPCRs. Comparable to Septerna's Native Complex® approach in addressing historically difficult-to-drug GPCR targets, with multiple partnered programs.

TypeBroad incumbent
Description

Established commercial-stage biopharma with a pipeline focused on neurological and rare disease therapies, including GPCR-targeted programs (pimavanserin). Relevant as a larger incumbent operating in adjacent GPCR therapeutic areas with both approved products and ongoing pipeline development.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics targeting modulators of the TGF-ß superfamily for hematological and musculoskeletal disorders. Comparable to Septerna in clinical-stage profile, rare-disease focus, and similar investor base, though differentiated on target class.

TypeEmerging player
Description

Computational drug discovery company combining physics-based simulation with machine learning to accelerate small molecule design across multiple therapeutic areas. Comparable to Septerna in platform-enabled small molecule discovery and partnership-heavy business model.

TypeEmerging player
Description

Late clinical-stage biopharma focused on liver and metabolic diseases, with commercial-stage MASH therapy Rezdiffra. Comparable to Septerna in clinical-stage evolution, metabolic disease focus, and small molecule oral therapeutic modality.

TypeDirect peer
Description

Clinical-stage biopharma developing GPCR-targeted therapeutics, with a historical focus on CNS and pain indications. Directly comparable to Septerna in GPCR specialization, small molecule approach, and clinical-stage profile.

TypeEmerging player
Description

Clinical-stage precision medicines company combining computational techniques with structural biology to drug previously intractable targets, including GPCRs and allosteric sites. Comparable to Septerna's structure-based drug design methodology and platform-driven pipeline approach.

TypeEmerging player
Description

Clinical-stage biopharma developing oral small molecule therapies for oncology and metabolic disease, including a GPCR-targeted obesity program. Comparable to Septerna in clinical-stage profile, oral small molecule modality, and metabolic disease focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Septerna

Clinical-stage biotechnology — GPCR-targeted therapeuticssepterna.com

What Septerna does

Septerna is a clinical-stage biotechnology company developing oral small molecule drug candidates that target G protein-coupled receptors (GPCRs), the largest family of cell membrane receptors and the target class for roughly one-third of all FDA-approved drugs. The company pursues a wholly-owned pipeline spanning endocrinology (SEP-479, an oral PTH1R agonist for hypoparathyroidism, and an oral TSHR negative allosteric modulator for Graves' disease and thyroid eye disease), immunology and inflammation (SEP-631, an oral MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell-driven diseases), and a partnered metabolic disease franchise under a global collaboration with Novo Nordisk covering five GPCR targets including GLP-1, GIP and glucagon receptors for obesity and cardiometabolic indications.

At the core of the company is the proprietary Native Complex Platform®, an industrial-scale drug discovery system that isolates, purifies and reconstitutes GPCRs outside of cells into complexes with ligands, transducer proteins and lipid bilayers, replicating native receptor structure and dynamics in a purified biochemical format. The platform integrates high-resolution cryo-EM structure determination with ultra-large-scale computational screening of billions of candidate molecules, biochemical screening via DNA-encoded libraries, and iterative structure-based drug design, and is supported by the scientific leadership of co-founder Robert Lefkowitz (Nobel laureate in GPCR research) alongside co-founders Arthur Christopoulos, Patrick Sexton and CEO Jeffrey Finer.

Septerna is pre-commercial and generates revenue primarily from collaboration agreements and asset sales rather than product sales. The dominant revenue stream is the May 2025 Novo Nordisk global collaboration and license agreement (~$2.2B total potential value: $195M upfront, up to ~$500M per program in milestones, plus tiered royalties on global net sales), with prior non-dilutive capital from the September 2023 sale of an undisclosed discovery-stage GPCR program to Vertex Pharmaceuticals for $47.5M upfront. Future product sales will rely on a hybrid GTM model combining independent commercialization of wholly-owned assets (SEP-479, SEP-631, TSHR program) with partner-led commercialization for the metabolic franchise, where Novo Nordisk funds all R&D expenses and brings established global commercial infrastructure. The company is publicly traded on NASDAQ under ticker SEPN following a 2024 IPO that raised $331M, and operates from South San Francisco with 51–100 employees.

Septerna firmographics

Firmographics
Name
Septerna
Legal name
Septerna, Inc.
Website
https://septerna.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Septerna industry classification

Industry
Product category
Clinical-stage biotechnology — GPCR-targeted therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • GPCR drug discovery
  • Oral small molecules
  • Clinical-stage biotechnology
  • Structure-based drug design
  • Cryo-EM drug discovery

Where Septerna is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Septerna business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Collaboration Revenue: Revenue generated from strategic partnerships with pharmaceutical companies including upfront payments, research and development funding, milestone payments, and tiered royalties on net sales of commercialized products. The company receives collaboration revenue from its Novo Nordisk partnership ($195M upfront plus potential milestones up to ~$500M per program plus royalties).
  2. Outbound Licensing and Asset Sales: Revenue from licensing or selling GPCR programs to pharmaceutical partners, including upfront payments and potential milestone payments. Example: Vertex Pharmaceuticals acquired an undisclosed discovery-stage GPCR program for $47.5M upfront plus potential preclinical milestones.
  3. Future Product Sales: Pre-commercial stage. The company is developing a pipeline of oral small molecule GPCR-targeted drug candidates that will be commercialized independently or through partnerships once approved. Peak sales projections for lead programs include SEP-631 ($3.2B for CSU) and SEP-479 ($2.5B for hypoparathyroidism).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Septerna product offering

Product offering

Core offering

Septerna is a clinical-stage biotechnology company that discovers and develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform®. The company is advancing a pipeline of wholly-owned programs across endocrinology (SEP-479 for hypoparathyroidism, TSHR Program for Graves' disease/thyroid eye disease), immunology and inflammation (SEP-631 for chronic spontaneous urticaria and mast cell-driven diseases), and metabolic diseases via a global partnership with Novo Nordisk covering five GPCR targets including GLP-1, GIP, and glucagon receptors for obesity and cardiometabolic indications.

Product overview

Septerna is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform®. The company's wholly-owned pipeline focuses on three therapeutic areas: endocrinology (SEP-479 for hypoparathyroidism, TSHR Program for Graves' disease and thyroid eye disease), immunology and inflammation (SEP-631 for chronic spontaneous urticaria and other mast cell-driven diseases), and metabolic diseases (via partnership with Novo Nordisk targeting GLP-1, GIP, and glucagon receptors for obesity and cardiometabolic diseases). Septerna develops oral small molecule drug candidates designed to have disease-modifying potential with distinct mechanisms of action including agonists and negative allosteric modulators targeting G protein-coupled receptors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Native Complex Platform® A proprietary industrial-scale drug discovery platform that enables the isolation, purification, and reconstitution of GPCRs outside of cells into complexes with ligands, transducer proteins, and lipid bilayers. The platform utilizes cryogenic electron microscopy for high-resolution 3D GPCR structure determination and supports screening of billions of candidate molecules through ultra-large-scale computational screens and DNA-encoded library biochemical screens, enabling structure-based drug design for previously difficult-to-drug GPCR targets.
  • SEP-479 (PTH1R agonist) An oral small molecule agonist targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. Designed to offer a convenient, functional replacement for PTH by activating PTH1R in bones and kidneys to restore normal calcium control, providing an oral alternative to injectable peptide-based therapies for the approximately 70,000 U.S. and 140,000 European patients affected by the disease.
  • SEP-631 (MRGPRX2 NAM) An oral small molecule negative allosteric modulator (NAM) that inhibits the Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases including atopic dermatitis, interstitial cystitis, migraine, and asthma. Targeted at approximately 1.5 million U.S. patients with CSU.
  • TSHR Program An oral small molecule negative allosteric modulator (NAM) targeting the thyroid-stimulating hormone receptor (TSHR) being developed for both Graves' disease and thyroid eye disease, offering a novel disease-modifying treatment approach for the over 2 million U.S. patients with Graves' disease, of whom approximately 50% develop thyroid eye disease.
  • Metabolic Programs (Novo Nordisk Collaboration) Global collaboration with Novo Nordisk to discover, develop and commercialize oral small molecule medicines for obesity and other cardiometabolic diseases, spanning five GPCR targets including GLP-1, GIP, and glucagon receptors. Septerna received $195 million upfront and is eligible for up to approximately $500 million in research, development and commercial milestone payments per program, plus tiered royalties on global net sales. Novo Nordisk is responsible for all R&D expenses.

Quantifiable outcome

  • SEP-631 demonstrated complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once-daily in Phase 1 trial
  • +3 more outcomes

Companies that use Septerna

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Septerna technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Septerna partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Novo NordiskflagshipStrategic or Co-development Partner · 1 May 2025Global collaboration and license agreement announced May 2025 to discover, develop and commercialize oral small molecule medicines for obesity and other cardiometabolic diseases. Programs span five GPCR targets including GLP-1, GIP, and glucagon receptors. Septerna received $195M upfront payment and is eligible for up to approximately $500M in research, development and commercial milestone payments for each program, plus tiered royalties on global net sales. Novo Nordisk responsible for all R&D expenses.
  • Vertex PharmaceuticalscoreStrategic or Co-development Partner · 1 September 2023Asset purchase agreement signed September 2023 under which Vertex acquired an undisclosed discovery-stage GPCR program. Septerna received $47.5M upfront payment and is eligible for additional payments related to use of the company's GPCR Native Complex Platform® and a preclinical milestone. Vertex responsible for continuing R&D of the novel GPCR program.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Septerna competitors and assessment

Company assessment

Direct peers

  • Structure Therapeutics: Clinical-stage biotech developing oral small molecule therapeutics targeting GPCRs, with a leading GLP-1 program for obesity and diabetes. Directly comparable to Septerna given the shared focus on oral small molecules against validated GPCR targets and similar cardiometabolic positioning.
  • Crinetics Pharmaceuticals: Clinical-stage biotech developing oral small molecule drugs targeting GPCRs in endocrinology and rare diseases, including acromegaly and hyperinsulinism programs. Highly comparable to Septerna's SEP-479 hypoparathyroidism positioning and oral small molecule GPCR strategy.
  • Sosei Heptares: Japan-headquartered GPCR-focused drug discovery company with a proprietary StaR® structural platform for stabilizing GPCRs. Comparable to Septerna's Native Complex® approach in addressing historically difficult-to-drug GPCR targets, with multiple partnered programs.
  • Keros Therapeutics: Clinical-stage biotech developing therapeutics targeting modulators of the TGF-ß superfamily for hematological and musculoskeletal disorders. Comparable to Septerna in clinical-stage profile, rare-disease focus, and similar investor base, though differentiated on target class.
  • Trevena: Clinical-stage biopharma developing GPCR-targeted therapeutics, with a historical focus on CNS and pain indications. Directly comparable to Septerna in GPCR specialization, small molecule approach, and clinical-stage profile.

Broad incumbents

  • Acadia Pharmaceuticals: Established commercial-stage biopharma with a pipeline focused on neurological and rare disease therapies, including GPCR-targeted programs (pimavanserin). Relevant as a larger incumbent operating in adjacent GPCR therapeutic areas with both approved products and ongoing pipeline development.

Emerging players

  • Schrödinger: Computational drug discovery company combining physics-based simulation with machine learning to accelerate small molecule design across multiple therapeutic areas. Comparable to Septerna in platform-enabled small molecule discovery and partnership-heavy business model.
  • Madrigal Pharmaceuticals: Late clinical-stage biopharma focused on liver and metabolic diseases, with commercial-stage MASH therapy Rezdiffra. Comparable to Septerna in clinical-stage evolution, metabolic disease focus, and small molecule oral therapeutic modality.
  • Relay Therapeutics: Clinical-stage precision medicines company combining computational techniques with structural biology to drug previously intractable targets, including GPCRs and allosteric sites. Comparable to Septerna's structure-based drug design methodology and platform-driven pipeline approach.
  • Terns Pharmaceuticals: Clinical-stage biopharma developing oral small molecule therapies for oncology and metabolic disease, including a GPCR-targeted obesity program. Comparable to Septerna in clinical-stage profile, oral small molecule modality, and metabolic disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Septerna social profiles

Digital presence

Septerna financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Septerna leadership team

Management profile

Number of profiles

Profiles7 records

Septerna funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Septerna M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Septerna

What does Septerna do?

Septerna is a clinical-stage biotechnology company that discovers and develops oral small molecule drug candidates targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform®. The company is advancing a pipeline of wholly-owned programs across endocrinology (SEP-479 for hypoparathyroidism, TSHR Program for Graves' disease/thyroid eye disease), immunology and inflammation (SEP-631 for chronic spontaneous urticaria and mast cell-driven diseases), and metabolic diseases via a global partnership with Novo Nordisk covering five GPCR targets including GLP-1, GIP, and glucagon receptors for obesity and cardiometabolic indications.

Is Septerna a public or private company?

Septerna is a public company. It is classified as public and is currently operating.

When was Septerna founded?

Septerna was founded in 2017. It employs 101 to 250 people.

Where is Septerna based?

Septerna is headquartered in South San Francisco, United States, in the North America region.

How does Septerna make money?

Three revenue lines are on record. Collaboration Revenue is the primary driver. The others are outbound Licensing and Asset Sales and future Product Sales.

Who are Septerna's main competitors?

Direct peers on record are Structure Therapeutics, Crinetics Pharmaceuticals, Sosei Heptares, Keros Therapeutics and Trevena. Acadia Pharmaceuticals is listed as a broad incumbent. Emerging players are Schrödinger, Madrigal Pharmaceuticals, Relay Therapeutics and Terns Pharmaceuticals.

Does Septerna have an API?

No public API is recorded for Septerna.

What industry is Septerna in?

Septerna's product category is Clinical-stage biotechnology — GPCR-targeted therapeutics. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewJP Morgan maintains Septerna at Overweight, raises price target to $51 from $48JP Morgan maintained Septerna at Overweight and raised its price target to $51 from $48, a 6.2% increase. The target implies a 29.3% upside from the Nov 18 close of $39.45. Recent analyst price targets range from $60 to $65.Seeking AlphaSepterna, Inc. (SEPN) Presents at UBS Global Biopharma Conference 2026 TranscriptSepterna, Inc. presented at the UBS Global Biopharma Conference, highlighting its GPCR-focused drug discovery platform. The company's oral small molecule SEP-479 for hypoparathyroidism is in Phase I, with results expected in Q1 2027.American Banking and Market NewsSepterna (NASDAQ:SEPN) Downgraded by Wall Street Zen to SellWall Street Zen downgraded Septerna from Hold to Sell, while other analysts like HC Wainwright and JPMorgan raised price targets. The stock opened at $42.60, with an average rating of Moderate Buy and a price target of $56.44. Septerna reported a loss of $0.57 per share, missing estimates.Simply Wall StAnalysts Have Lowered Expectations For Septerna, Inc. (NASDAQ:SEPN) After Its Latest ResultsSepterna reported Q3 revenue of $19m, missing estimates by 9.1%, and a statutory loss of $0.57 per share. Analysts now forecast 2027 revenue of $68.7m, down 29% from prior year, and per-share losses of $2.41. The consensus price target was raised 9.2% to $59.22.Seeking AlphaSepterna, Inc. GAAP EPS of -$0.57, revenue of $18.88M (SEPN:NASDAQ)Septerna, Inc. reported Q3 GAAP EPS of -$0.57 and revenue of $18.88 million. The company's stock closed at $50.74, up 3.87% from the previous close of $48.85.TradingViewWells Fargo maintains Septerna at Overweight, raises price target to $61 from $50Wells Fargo maintained Septerna at Overweight and raised its price target to $61 from $50, a 22% increase. The target implies a 39.6% upside from the Nov 3 close of $43.70.TradingViewSepterna Selects SEP-204 for Graves’ Disease and TED, Plans Phase 1 in Q1 2027Septerna selected SEP-204 as a development candidate for Graves' disease and thyroid eye disease, reporting promising preclinical findings. The oral TSHR negative allosteric modulator restored normal T4 levels and reduced thyroid enlargement in animal models, with a projected human half-life of 20–40 hours. Septerna plans to initiate a Phase 1 trial in healthy volunteers in the first quarter of 2027.Markets DailyComparing Septerna (NASDAQ:SEPN) and INmune Bio (NASDAQ:INMB)Septerna and INmune Bio are compared on profitability, risk, valuation, and analyst ratings. Septerna beats INmune Bio on 8 of 13 factors, with a consensus price target of $52.44 implying 29.78% upside. Analysts favor Septerna over INmune Bio.American Banking and Market NewsSepterna, Inc. (NASDAQ:SEPN) Stock Now Rated “Moderate Buy” by Sell-Side BrokeragesSepterna's stock received an average "Moderate Buy" rating from eleven brokerages, with an average price target of $52.44. The company reported Q2 EPS of -$0.29, beating estimates, and insiders sold 31,667 shares in the last 90 days.MarketBeatSepterna, Inc. (SEPN) - What Are Researchers Thinking About This Stock?Analysts rate Septerna a Moderate Buy with an average 12-month price target of $52.44. The company reported Q2 EPS of -$0.29, beating estimates, with revenue of $26.75 million. Insiders sold 31,667 shares over three months.